

Application No. 10,564,647  
Amendment Dated June 1, 2009  
Reply to Office Action of March 31, 2009

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUN 01 2009**

**Remarks/Arguments:**

In response to the restriction requirement dated March 31, 2009, Applicants elect Group 1. Group 1 includes claims 1, 3, and 4-21.

Upon entry of the present amendment, claims 1, 3, 4-21, 24-25 are pending, claims 22-23, 26-34, and 41-55 having been canceled and claims 56-58 and 61 having been withdrawn. Applicants have withdrawn the process claims relating to the product of Group 1 and request rejoinder once the product claims have been deemed allowable.

The Examiner has further required the election of species. Applicants elect the specific binding member for IL-13 where the antibody of claim 1 has one or two substitutions where at least one substitution is an S at position 99 of HCDR3.

Claims that read on the elected species include currently pending claims 3-21 and 24-25.


The above amendments have been made without prejudice to Applicants' right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 102789-1P US.

Respectfully submitted,

/Christine McCormack/



Name: Christine McCormack  
Dated: June 1, 2009  
Reg. No.: 61,331  
Phone No.: 781-839-4693  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatchouse Drive,  
Waltham, MA 02451